Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Long-Term Investments (2020 - 2025)

Historic Long-Term Investments for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q3 2025 value amounting to $2.5 million.

  • Mirum Pharmaceuticals' Long-Term Investments fell 7350.07% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 7350.07%. This contributed to the annual value of $12.5 million for FY2024, which is N/A changed from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Long-Term Investments stood at $2.5 million for Q3 2025, which was down 7350.07% from $17.1 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Long-Term Investments ranged from a high of $20.9 million in Q1 2025 and a low of $2.5 million during Q3 2025
  • Moreover, its 3-year median value for Long-Term Investments was $15.0 million (2021), whereas its average is $12.7 million.
  • Over the last 5 years, Mirum Pharmaceuticals' Long-Term Investments had its largest YoY gain of 21.67% in 2025, and its largest YoY loss of 7350.07% in 2025.
  • Mirum Pharmaceuticals' Long-Term Investments (Quarter) stood at $5.0 million in 2021, then soared by 151.37% to $12.5 million in 2024, then plummeted by 80.28% to $2.5 million in 2025.
  • Its Long-Term Investments was $2.5 million in Q3 2025, compared to $17.1 million in Q2 2025 and $20.9 million in Q1 2025.